MK-1421

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C27H24FN9O2
Molecular Weight	525.537
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCN1C=C(C=N1)[C@]2(N[C@H](CC3=C2NC4=C3C=CC=C4)C5=NC(=CN5)C6=NC=C(F)C=C6)C7=NN(C)C(=O)O7

InChI

InChIKey=RETOYYSEVCBIRN-JIPXPUAJSA-N

InChI=1S/C27H24FN9O2/c1-3-37-14-15(11-31-37)27(25-35-36(2)26(38)39-25)23-18(17-6-4-5-7-19(17)32-23)10-21(34-27)24-30-13-22(33-24)20-9-8-16(28)12-29-20/h4-9,11-14,21,32,34H,3,10H2,1-2H3,(H,30,33)/t21-,27-/m1/s1

HIDE SMILES / InChI

Molecular Formula	C27H24FN9O2
Molecular Weight	525.537
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Approval Year

Substance Class	Chemical Created by `admin` on `Sat Dec 16 08:44:43 GMT 2023` Edited by `admin` on `Sat Dec 16 08:44:43 GMT 2023`
Record UNII	N9WN9W54QJ
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

MK-1421

Code

English

1,3,4-OXADIAZOL-2(3H)-ONE, 5-((1R,3R)-1-(1-ETHYL-1H-PYRAZOL-4-YL)-3-(5-(5-FLUORO-2-PYRIDINYL)-1H-IMIDAZOL-2-YL)-2,3,4,9-TETRAHYDRO-1H-PYRIDO(3,4-B)INDOL-1-YL)-3-METHYL-

Systematic Name

English

MK1421

Code

English

5-((1R,3R)-1-(1-ETHYL-1H-PYRAZOL-4-YL)-3-(5-(5-FLUORO-2-PYRIDINYL)-1H-IMIDAZOL-2-YL)-2,3,4,9-TETRAHYDRO-1H-PYRIDO(3,4-B)INDOL-1-YL)-3-METHYL-1,3,4-OXADIAZOL-2(3H)-ONE

Systematic Name

English

Code System Code Type Description

CAS

1235995-16-0

Created by admin on Sat Dec 16 08:44:43 GMT 2023 , Edited by admin on Sat Dec 16 08:44:43 GMT 2023

PRIMARY

PUBCHEM

122179477

Created by admin on Sat Dec 16 08:44:43 GMT 2023 , Edited by admin on Sat Dec 16 08:44:43 GMT 2023

PRIMARY

FDA UNII

N9WN9W54QJ

Created by admin on Sat Dec 16 08:44:43 GMT 2023 , Edited by admin on Sat Dec 16 08:44:43 GMT 2023

PRIMARY

Related Record Type Details


					N9WN9W54QJ

MK-1421

ACTIVE MOIETY

Comments:

MK-1421 sstr3 binding IC50 = 2.3 NM. , sstr3 func. antag IC50 = 1.1 NM. ABSTRACT: The imidazolyl-tetrahydro-.BETA.-carboline class of sstr3 antagonists have demonstrated efficacy in a murine model of glucose excursion and may have potential as a treatment for type 2 diabetes. The first candidate in this class caused unacceptable QTc interval prolongation in oral, telemetrized cardiovascular (CV) dogs. Herein, we describe our efforts to identify an acceptable candidate without CV effects. These efforts resulted in the identification of (1R,3R)-3-(4-(5-fluoropyridin-2-yl)-1H-imidazol-2-yl)-1-(1-ethyl-pyrazol-4- yl)-1-(3-methyl-1,3,4-oxadiazol-3H-2-one-5-yl)-2,3,4,9-tetrahydro-1H-.BETA.-carboline (17e, MK-1421).